Omega-3-acid ethyl esters

Omega-3-acid ethyl esters
Chemical structure of ethyl eicosapentaenoate, an important omega-3-acid ethyl ester
Combination of
Ethyl eicosapentaenoateAntilipemic agent
Ethyl docosahexaenoateAntilipemic agent
Clinical data
Trade namesLovaza, Omacor, others
Other namesEthyl polyenoate (ChP)[1]
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem SID
DrugBank
UNII
KEGG
ChEMBL

Omega-3-acid ethyl esters are a mixture of ethyl eicosapentaenoate and ethyl docosahexaenoate, which are ethyl esters of the omega−3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in fish oil.[5] Together with dietary changes, they are used to treat high blood triglycerides which may reduce the risk of pancreatitis.[5][6] They are generally less preferred than statins, and use is not recommended by NHS Scotland as the evidence does not support a decreased risk of heart disease.[5][7][8] Omega-3-acid ethyl esters are taken by mouth.[5]

Common side effects include burping, nausea, and an upset abdomen.[5][7] Serious side effects may include liver problems and anaphylaxis.[5] While use in pregnancy has not been well studied, some omega−3 fatty acids appear beneficial.[2] How it works is not entirely clear.[5]

Experts found a dose-dependent increase in the risk for atrial fibrillation in patients with cardiovascular diseases or cardiovascular risk factors who were being treated with omega-3-acid ethyl esters compared with those treated with placebo. The observed risk was at its highest at a dose of 4 g/d.[1]

Omega-3-acid ethyl ester medicines were approved for medical use in the European Union in 2000 and in the United States in 2004.[5][8][9] Beyond the branded prescription formulation, it is also available as a generic medication and over the counter.[5][7] In 2022, it was the 220th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[10][11]

  1. ^ "多烯酸乙酯". 中国药典 (in Chinese). Vol. 2 (2015 ed.). p. 384.
  2. ^ a b "Omega-3 polyunsaturated fatty acids Use During Pregnancy". Drugs.com. Retrieved 13 April 2019.
  3. ^ Cite error: The named reference emc was invoked but never defined (see the help page).
  4. ^ "Lovaza- omega-3-acid ethyl esters capsule, liquid filled". DailyMed. 3 February 2021. Retrieved 24 November 2024.
  5. ^ a b c d e f g h i "Omega-3-acid Ethyl Esters Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 13 April 2019.
  6. ^ Karalis DG (February 2017). "A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids". Advances in Therapy. 34 (2): 300–323. doi:10.1007/s12325-016-0462-y. PMC 5331085. PMID 27981496.
  7. ^ a b c British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 206–207. ISBN 9780857113382.
  8. ^ a b "Omega-3 fatty acid medicines". European Medicines Agency. 17 September 2018. Retrieved 13 April 2019.
  9. ^ "Drug Approval Package: Omacor (Omega-3-Acid Ethyl Esters) NDA #021654". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 15 May 2020.
  10. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  11. ^ "Omega-3-acid Ethyl Esters Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.